{"id":18579,"date":"2015-05-05T11:31:10","date_gmt":"2015-05-05T09:31:10","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=18579"},"modified":"2015-05-05T12:40:00","modified_gmt":"2015-05-05T10:40:00","slug":"migliorare-aderenza-cure-del-10-obiettivo-industrie","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/migliorare-aderenza-cure-del-10-obiettivo-industrie\/","title":{"rendered":"Improve adherence cures of the 10% target industries"},"content":{"rendered":"<p><em>According to the survey, two out of three plan or have ad hoc initiatives underway<\/em><\/p>\n<p><img decoding=\"async\" class=\"alignleft\" src=\"http:\/\/www.thepharmaletter.com\/media\/image\/eye-for-pharma.jpg\" alt=\"\" \/>Adherence to therapies is at the heart of the communication and information projects of pharmaceutical companies. In fact, two out of three have or are developing initiatives aimed at raising awareness of the importance of following the treatment with constancy and precision.<\/p>\n<p>This is what emerges from a <a href=\"http:\/\/social.eyeforpharma.com\/commercial\/pharma-gets-serious-about-drug-adherence\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">survey<\/span> <\/a>out of 200 companies (American 29.3% of the sample; multinationals 16%; European 36.2%; Asia-Pacific area 9.8%; Middle East\/Africa 4%; South America 4.6%) conducted by &#039;Eyeforpharma&#039;. Interviewees reported the use of management services, education projects and &#039;coaching&#039; on adherence to care, all strictly on the Internet, as well as SMS reminders and ad hoc devices to help deal with the problem.<\/p>\n<p>The data demonstrates that pharmaceutical companies are both clinically and financially motivated to address the issue: 97% of the managers surveyed believe that lack of adherence primarily affects patient outcomes, but 84% indicates that there is also a significant impact on the revenues of the companies themselves. And while perfect fit is clearly not possible, respondents&#039; 87% believe it could be improved by at least the 10%.<\/p>\n<p>If this improvement were achieved, analysts calculate that it would boost the companies&#039; sales by an amount equivalent to the entire Japanese market. According to the research, this can only happen by exploiting the potential of new technologies (the 72% of companies are convinced of this), in which there is a strong willingness to invest: 2 out of 3 respondents expect a growth in funds over the next three years , with 20% predicting an increase greater than 50% from current levels.<\/p>\n<p><span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"http:\/\/streamer.adnkronos.com\/Salute\/Newsletter\/data\/Pk80e15.pdf\" target=\"_blank\" rel=\"noopener\">Barbara Di Chiara \u2013 5 May 2015 \u2013 Pharma<em>Kronos<\/em><\/a><\/span><\/p>\n<p>Related news:\u00a0<a href=\"http:\/\/www.corriere.it\/salute\/15_maggio_05\/non-mi-curo-medico-non-sa-scarsa-aderenza-terapie-2efe1ccc-f306-11e4-a9b9-3b8b5258745e.shtml\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">I don&#039;t treat myself and the doctor doesn&#039;t know it. Poor adherence to therapies<\/span><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter\" src=\"http:\/\/www.corriere.it\/methode_image\/2015\/05\/05\/Salute\/Foto%20Salute\/51.jpg?v=20150505113026\" alt=\"\" width=\"1088\" height=\"814\" \/><\/p>","protected":false},"excerpt":{"rendered":"<p>Il sondaggio, due su tre progettano o hanno in corso iniziative ad hoc L&#8217;aderenza alle terapie \u00e8 al centro dei progetti di comunicazione e informazione delle aziende farmaceutiche. Due su tre, infatti, hanno in corso o stanno mettendo a punto iniziative volte proprio a sensibilizzare sull&#8217;importanza di seguire il trattamento con costanza e precisione. E&#8217; &hellip;<\/p>","protected":false},"author":4,"featured_media":18582,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[47],"class_list":["post-18579","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-big-pharma"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/18579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=18579"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/18579\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/18582"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=18579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=18579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=18579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}